RxDoctor Payments Data

Vanousheh Ghandhari, DPM

Foot & Ankle Surgery · Chandler, AZNPI 1821409129

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Paragon 28, Inc. at 26.0% of the total. Reporting peaked in 2021 at $4,371 and has fallen 83.2% since, to $735 in 2025.

$11,433in general payments, 2019–2025

Across 153 payments — averaging $74.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$3K
  • Arthrex$2K
  • Stryker$2K
  • Treace Medical Concepts, Inc.$2K
  • Impactortho, Inc.$737
  • DJO, LLC$672
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$4,23637%
  • Food & beverage$5,40147%
  • Education$1,79616%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,433 in reported general payments places this provider in the 80th percentile of 291 foot & ankle surgery providers in Arizona.

See all foot & ankle surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$348,497
Medicare patients
438
Services billed
4,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$8,215
Ciclopirox70$1,656
Gabapentin82$791
Methylprednisolone94$696
Cephalexin87$678
Nitro-BidNitroglycerin13$650
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen31$396
Diclofenac Potassium13$334
Doxycycline Hyclate20$218
Colchicine11$186
Terbinafine Hcl19$183
Allopurinol18$136
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$101
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$34$8,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 291 foot & ankle surgery providers in Arizona.

Other foot & ankle surgery in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →